Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Rating of “Hold” from Analysts
by Teresa Graham · The Cerbat GemFractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) has been given a consensus rating of “Hold” by the five research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.40.
A number of brokerages recently issued reports on GUTS. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $8.00 to $2.00 in a research note on Thursday, January 29th.
Get Our Latest Stock Analysis on Fractyl Health
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in GUTS. Jane Street Group LLC bought a new position in Fractyl Health in the second quarter valued at approximately $31,000. FNY Investment Advisers LLC bought a new position in Fractyl Health in the 3rd quarter valued at approximately $31,000. Scientech Research LLC acquired a new stake in Fractyl Health in the third quarter valued at approximately $49,000. Prelude Capital Management LLC acquired a new stake in Fractyl Health in the third quarter valued at approximately $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Fractyl Health in the third quarter valued at approximately $56,000.
Fractyl Health Stock Up 1.1%
NASDAQ GUTS opened at $0.58 on Tuesday. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 3.23. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03. The company has a 50 day moving average of $0.47 and a 200-day moving average of $1.21. The company has a market cap of $91.30 million, a price-to-earnings ratio of -0.31 and a beta of 1.20.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. On average, equities research analysts expect that Fractyl Health will post -0.67 earnings per share for the current fiscal year.
About Fractyl Health
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.